The Global Penicillin Drug Market size is expected to reach $10.9 billion by 2030, rising at a market growth of 3.6% CAGR during the forecast period.
Due to factors like the rising prevalence of infectious diseases, better healthcare infrastructure, key market players, and expanding awareness campaigns, North America region is expected to register more than 25% share of the market by 2030. According to Canadian Cancer Statistics, 45% of men and 43% of women in Canada will have cancer at some point in their lives. As the population of Canada ages and grows larger, the prevalence of new cancer cases has been continuously increasing in different cancers like throat, and lungs. Also, the growing elderly and pediatric populations in the region, who are more vulnerable to contracting infectious diseases because of low immunity, are anticipated to support the expansion of market.
The major strategies followed by the market participants are Partnerships as the key developmental strategy in order to keep pace with the changing demands of end users. For instance, In September, 2022, GlaxoSmithKline PLC partnered with Spero Therapeutics, Inc. to use Spero's tebipenem pivoxil hydrobromide antibiotic drug and allow GlaxoSmithKline to offer better treatment options for patients with urinary tract infections. Moreover, In March,2021, Cipla Limited entered a partnership with SIGA Technologies, Inc. to develop solutions for novel antibacterial drugs for countering biothreats.
Based on the Analysis presented in the KBV Cardinal matrix; Pfizer, Inc. is the forerunner in the Market. In January, 2022, Pfizer, Inc. came into partnership with Becton, Dickinson, and Company to develop solutions for the correct use of antimicrobial drugs. Companies such as GlaxoSmithKline PLC (GSK), Novartis AG, Abbott Laboratories are some of the key innovators in the Market.
Diseases caused by bacteria significantly impact the public's health. Anybody may acquire the disease, which can be brought on either by the organism itself or by the body's reaction to its existence. Humans can contract bacteria via food, water, the air, or living things. The medication destroys the enzymes that help bacteria form their cell walls. For different infections, different types of penicillin are utilized. Amoxicillin, ampicillin, Augmentin, penicillin G, and penicillin V are a few varieties of penicillin. In consideration to the above-mentioned elements, it is projected that the expanding bacterial infection will boost the expansion of the market.
Developing and bringing new antibiotics to market is a difficult task. Still, it must be accomplished if the person is better protected against the rising threat of drug-resistant illnesses. Modern medicine has revolutionized since the first antibiotic, penicillin, was discovered. Bacteria will ultimately acquire resistance to the new medications. Also, they require advancements in creating diagnostics, vaccinations, and better prevention, control, and monitoring to stay ahead of the never-ending battle against superbugs. According to the WHO, 40 to 50 antibiotics are in clinical development. As a result, this market will grow in the next years due to the increasing demand for antibiotics.
One of the biggest issues affecting the healthcare system is antibiotic resistance, which presents a significant risk to public health. These strains were initially isolated to the hospital environment but are now prevalent. The causes identified as causing the spread of antibiotic resistance include globalization, aquaculture, the use of several broad-spectrum drugs, excessive use of antibiotics in animal husbandry, and a lack of proper antimicrobial stewardship. Given the rise in antibiotic-resistant organisms, there must be fewer antimicrobial medicines available to treat diseases.
On the basis of source, the market is segmented into natural penicillin, and semisynthetic penicillin. The natural penicillin acquired a substantial revenue share in the market in 2022. Natural penicillins are efficient against both gram-positive and gram-negative bacteria, including Borrelia, streptococci, meningococci, staphylococci, Treponema, and Leptospira. Penicillin V is only for oral use, and penicillin G is for parenteral use. Except for Bacteroides fragilis, these medications are most often used to diagnose diseases brought on by gram-positive bacteria, including anaerobes.
By spectrum of activity, the market is categorised into narrow spectrum, broad spectrum, and extended spectrum. In 2022, the broad-spectrum segment witnessed the largest revenue share in the market. Infections of the throat, ear, nasal sinuses, respiratory tract (such as pneumonia), urinary tract, skin and soft tissue, and typhoid fever can all be treated with broad-spectrum penicillins, a class of antibiotics related to penicillin. Ampicillin and its esters, which include bacapicillin, pivampicillin, and talampicillin, as well as amoxycillin, co-amoxiclav, and mezlocillin are the major broad-spectrum penicillins.
On the basis of distribution channel, the market is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. The online providers segment projected a prominent revenue share in the market in 2022. Penicillin drugs are available through several online vendors, enabling consumers to find certain brands, doses, and formulations that suit their unique needs. Additionally, users can shop online at any time because of the platforms' 24/7 availability. These factors will lead the growth in this segment.
Based on route of administration, the market is classified into oral, and parenteral. In 2022, the parenteral segment held the highest revenue share in the market. Due to the increased use of penicillin injections for the treatment of serious bacterial infections and the rise in syphilis prevalence, for which penicillin G injections are the primary treatment. Sometimes, parenteral administration is favored over other drug delivery methods, such as cardiac arrest and anaphylactic shock emergencies.
| Report Attribute | Details |
|---|---|
| Market size value in 2022 | USD 8.3 Billion |
| Market size forecast in 2030 | USD 10.9 Billion |
| Base Year | 2022 |
| Historical Period | 2019 to 2021 |
| Forecast Period | 2023 to 2030 |
| Revenue Growth Rate | CAGR of 3.6% from 2023 to 2030 |
| Number of Pages | 284 |
| Number of Table | 424 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Companies Strategic Developments, Company Profiling |
| Segments covered | Source, Spectrum of Activity, Distribution Channel, Route of Administration, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Region wise, the market is analysed into North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region led the market by generating highest revenue share. The growth can be related to the region's rising incidence of infectious diseases and the rising demand for penicillin drugs. With the expanding populations of nations like China and India, the Asia-Pacific region is one of the greatest markets for antibiotics, including the penicillin drugs. Furthermore, the Asia-Pacific market has expanded significantly due to factors like rising healthcare costs, improved healthcare infrastructure, rising antibiotic usage knowledge, and the presence of major pharmaceutical companies in the region.
Free Valuable Insights: Global Penicillin Drug Market size to reach USD 10.9 Billion by 2030
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Novartis AG, Lupin Limited, Abbott Laboratories, Cipla Limited, Takeda Pharmaceutical Company Limited, Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.
By Source
By Spectrum of Activity
By Distribution Channel
By Route of Administration
By Geography
The Market size is projected to reach USD 10.9 billion by 2030.
Increasing Demand for Efficient and Modern Antibiotics are driving the Market in coming years, however, Rise In Multi-Drug Resistant (MDR) Infections restraints the growth of the Market.
GlaxoSmithKline PLC (GSK), Pfizer, Inc., Novartis AG, Lupin Limited, Abbott Laboratories, Cipla Limited, Takeda Pharmaceutical Company Limited, Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd.
The Drug Stores & Retail Pharmacies segment acquired maximum revenue share in the Market by Distribution Channel in 2022; thereby, achieving a market value of $4.9 billion by 2030.
The Semisynthetic Penicillin segment is leading the Market by Source in 2022; thereby, achieving a market value of $8.8 billion by 2030.
The Asia Pacific region dominated the Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $4.2 billion by 2030.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 